These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28790016)

  • 1. Tau-imaging in neurodegeneration.
    Bischof GN; Endepols H; van Eimeren T; Drzezga A
    Methods; 2017 Nov; 130():114-123. PubMed ID: 28790016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau imaging with PET: an overview of challenges, current progress, and future applications.
    Robertson JS; Rowe CC; Villemagne VL
    Q J Nucl Med Mol Imaging; 2017 Dec; 61(4):405-413. PubMed ID: 28750496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau Imaging in Neurodegenerative Diseases Using Positron Emission Tomography.
    Wang YT; Edison P
    Curr Neurol Neurosci Rep; 2019 Jun; 19(7):45. PubMed ID: 31172290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer's Tauopathy.
    Murugan NA; Nordberg A; Ågren H
    ACS Chem Neurosci; 2021 Jul; 12(13):2437-2447. PubMed ID: 34152739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Amyloid PET Imaging Biomarkers for Neurodegeneration: Focus on Tau, Alpha-Synuclein and Neuroinflammation.
    Catafau AM; Bullich S
    Curr Alzheimer Res; 2017; 14(2):169-177. PubMed ID: 27334945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Imaging Insights into Neurodegeneration: Focus on Tau PET Radiotracers.
    Shah M; Catafau AM
    J Nucl Med; 2014 Jun; 55(6):871-4. PubMed ID: 24833492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developments in Tau PET Imaging.
    Zimmer ER; Leuzy A; Gauthier S; Rosa-Neto P
    Can J Neurol Sci; 2014 Sep; 41(5):547-53. PubMed ID: 25424608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau PET Imaging.
    Higuchi M
    Adv Exp Med Biol; 2019; 1184():217-230. PubMed ID: 32096041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the development of tau PET radiotracers and their clinical applications.
    Okamura N; Harada R; Furukawa K; Furumoto S; Tago T; Yanai K; Arai H; Kudo Y
    Ageing Res Rev; 2016 Sep; 30():107-13. PubMed ID: 26802556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias.
    Wren MC; Lashley T; Årstad E; Sander K
    Acta Neuropathol Commun; 2018 May; 6(1):34. PubMed ID: 29716656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau PET imaging: present and future directions.
    Saint-Aubert L; Lemoine L; Chiotis K; Leuzy A; Rodriguez-Vieitez E; Nordberg A
    Mol Neurodegener; 2017 Feb; 12(1):19. PubMed ID: 28219440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo tau imaging: obstacles and progress.
    Villemagne VL; Okamura N
    Alzheimers Dement; 2014 Jun; 10(3 Suppl):S254-64. PubMed ID: 24924676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808.
    Chien DT; Szardenings AK; Bahri S; Walsh JC; Mu F; Xia C; Shankle WR; Lerner AJ; Su MY; Elizarov A; Kolb HC
    J Alzheimers Dis; 2014; 38(1):171-84. PubMed ID: 23948934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue.
    Aguero C; Dhaynaut M; Normandin MD; Amaral AC; Guehl NJ; Neelamegam R; Marquie M; Johnson KA; El Fakhri G; Frosch MP; Gomez-Isla T
    Acta Neuropathol Commun; 2019 Mar; 7(1):37. PubMed ID: 30857558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau imaging in neurodegenerative diseases.
    Dani M; Brooks DJ; Edison P
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1139-50. PubMed ID: 26572762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
    Watanabe H
    Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brief update on different roles of tau in neurodegeneration.
    Ittner A; Ke YD; van Eersel J; Gladbach A; Götz J; Ittner LM
    IUBMB Life; 2011 Jul; 63(7):495-502. PubMed ID: 21698753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disclosing tau tangles using PET imaging: a pharmacological review of the radiotracers available in 2021.
    Van Wambeke É; Gérard T; Lhommel R; Hanseeuw B
    Acta Neurol Belg; 2022 Apr; 122(2):263-272. PubMed ID: 34713414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discriminatory ability of next-generation tau PET tracers for Alzheimer's disease.
    Yap SY; Frias B; Wren MC; Schöll M; Fox NC; Årstad E; Lashley T; Sander K
    Brain; 2021 Sep; 144(8):2284-2290. PubMed ID: 33742656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions.
    Villemagne VL; Okamura N
    Curr Opin Neurobiol; 2016 Feb; 36():43-51. PubMed ID: 26397020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.